Bayer to acquire Asklepios BioPharmaceutical for up to $4bn
As per terms of the deal, Asklepios will secure an upfront consideration of $2bn and potential success-based milestone payments of up to $2bn from Bayer. Based in North
Kyowa Kirin subsidiary Kyowa Kirin EMEA has received approval from the European Commission (EC) to expand the use of Crysvita (burosumab) for treating X-linked hypophosphataemia (XLH) in infants aged one month to one year across the EU and European Economic Area.
Under the terms of the agreement EffRx has received the exclusive rights to register and commercialize Alkindi in Switzerland. Alkindi is the first preparation of hydrocortisone specifically designed